Journal
RESPIROLOGY
Volume 28, Issue 3, Pages 212-214Publisher
WILEY
DOI: 10.1111/resp.14399
Keywords
interstitial lung disease; phosphodiesterase type 5 inhibitor; pulmonary fibrosis; pulmonary hypertension; sildenafil; tadalafil; treatment